



STAMFORD
PHARMACEUTICALS INC

Stamford Pharmaceuticals announced today that Associate Professors Greg Siller and Sherrif Ibrahim will be Principal Investigators for the company's initial Pilot phase of its registration program in Australia and the US

August 1st, 2019 Stamford Pharmaceuticals announced today the engagement with Assoc. Professors Greg Siller and Sherrif Ibrahim to serve as lead investigators and initial centers for the company's registration program. The company had previously completed a Phase 1/2 clinical study in low risk nodular basal cell carcinoma patients with both the sporadic and Basal Cell Nevus Syndrome patient populations. All eligible participants on study responded to treatment with 83% showing complete histological clearance of their cancers at week 16/17 post commencement of treatment. The remaining lesions demonstrated partial clinical responses and on-going regression at the end of the study evaluation period. The current Pilot phase of the registration program serves to extend the evaluation time-points to assess prospects of further improvement in the response rate. The Pilot program will also evaluate the treatment of subjects with multiple basal cell carcinoma lesions. The Pilot phase will also evaluate combination treatments with specific pathway inhibitors that are anticipated to demonstrate synergistic efficacy.

Dr Greg Siller is an Adjunct Associate Professor at The University of Queensland, Australia, a Senior Visiting Dermatologist at the Princess Alexandra Hospital and owner of Central Brisbane Dermatology where he runs his private practice and clinical trial unit. He has proven experience in clinical development and trials for novel therapies for non-melanoma skin cancers.

Dr. Sherrif F. Ibrahim is an Associate Professor of Dermatology at the University of Rochester Medical Center and Owner of Rochester Dermatologic Surgery, P.C. His practice is dedicated to the diagnosis, treatment and prevention of skin cancer using Mohs surgery and other state of the art techniques. His research is positioned at the intersection of science and medicine, focussing on developing new methods for the treatment of these diseases.

-END-

About Stamford pharmaceuticals

Stamford pharmaceuticals is clinical stage immunology and inflammation focused company developing rational combination therapies that aim to improve patient lives. Cancers are complex dynamic and adaptive diseases where the tumor micro-environment comprises many different cell types, matrix proteins and secreted molecules. These elements form a highly redundant regulatory network that enables continued tumor survival, adaptation and progression even in the face of potent treatments. There is clear evidence that single-target drugs do not provide durable outcomes for many patients. We believe that taking a network multi-target approach offer a better opportunity to improving response rates and durability by maximizing synergistic efficacy while reducing off-target toxicities.



STAMFORD
PHARMACEUTICALS INC

Please visit stamfordpharmaceuticals.com

Company Contact:

Clement Leong

Stamford Pharmaceuticals,

CEO

E: clementleong@stamfordpharma.com

Investor Relations Contact:

The Ruth Group

T: 646 536 7035

E: tbui@theruthgroup.com